216 related articles for article (PubMed ID: 20713032)
1. Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts.
Hsu SH; Lai MC; Er TK; Yang SN; Hung CH; Tsai HH; Lin YC; Chang JG; Lo YC; Jong YJ
Clin Chim Acta; 2010 Dec; 411(23-24):1920-8. PubMed ID: 20713032
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of UCHL1 are a compensatory response to disrupted ubiquitin homeostasis in spinal muscular atrophy and do not represent a viable therapeutic target.
Powis RA; Mutsaers CA; Wishart TM; Hunter G; Wirth B; Gillingwater TH
Neuropathol Appl Neurobiol; 2014 Dec; 40(7):873-87. PubMed ID: 25041530
[TBL] [Abstract][Full Text] [Related]
3. Survival of motor neuron protein downregulates miR-9 expression in patients with spinal muscular atrophy.
Wang LT; Chiou SS; Liao YM; Jong YJ; Hsu SH
Kaohsiung J Med Sci; 2014 May; 30(5):229-34. PubMed ID: 24751385
[TBL] [Abstract][Full Text] [Related]
4. Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice.
Hsu YY; Jong YJ; Tsai HH; Tseng YT; An LM; Lo YC
Br J Pharmacol; 2012 Jun; 166(3):1114-26. PubMed ID: 22220673
[TBL] [Abstract][Full Text] [Related]
5. Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy.
Tseng YT; Chen CS; Jong YJ; Chang FR; Lo YC
Pharmacol Res; 2016 Sep; 111():58-75. PubMed ID: 27241020
[TBL] [Abstract][Full Text] [Related]
6. The expression of SMN1, MART3, GLE1 and FUS genes in spinal muscular atrophy.
Alrafiah A; Alghanmi M; Almashhadi S; Aqeel A; Awaji A
Folia Histochem Cytobiol; 2018; 56(4):215-221. PubMed ID: 30565205
[TBL] [Abstract][Full Text] [Related]
7. The survival motor neuron protein in spinal muscular atrophy.
Coovert DD; Le TT; McAndrew PE; Strasswimmer J; Crawford TO; Mendell JR; Coulson SE; Androphy EJ; Prior TW; Burghes AH
Hum Mol Genet; 1997 Aug; 6(8):1205-14. PubMed ID: 9259265
[TBL] [Abstract][Full Text] [Related]
8. Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway.
Chang HC; Hung WC; Chuang YJ; Jong YJ
Neurochem Int; 2004 Dec; 45(7):1107-12. PubMed ID: 15337310
[TBL] [Abstract][Full Text] [Related]
9. Blocking p62-dependent SMN degradation ameliorates spinal muscular atrophy disease phenotypes.
Rodriguez-Muela N; Parkhitko A; Grass T; Gibbs RM; Norabuena EM; Perrimon N; Singh R; Rubin LL
J Clin Invest; 2018 Jul; 128(7):3008-3023. PubMed ID: 29672276
[TBL] [Abstract][Full Text] [Related]
10. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts.
Mattis VB; Rai R; Wang J; Chang CW; Coady T; Lorson CL
Hum Genet; 2006 Nov; 120(4):589-601. PubMed ID: 16951947
[TBL] [Abstract][Full Text] [Related]
11. Survival Motor Neuron Protein is Released from Cells in Exosomes: A Potential Biomarker for Spinal Muscular Atrophy.
Nash LA; McFall ER; Perozzo AM; Turner M; Poulin KL; De Repentigny Y; Burns JK; McMillan HJ; Warman Chardon J; Burger D; Kothary R; Parks RJ
Sci Rep; 2017 Oct; 7(1):13859. PubMed ID: 29066780
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
[TBL] [Abstract][Full Text] [Related]
13. In vitro gene manipulation of spinal muscular atrophy fibroblast cell line using gene-targeting fragment for restoration of SMN protein expression.
Rashnonejad A; Gündüz C; Süslüer SY; Onay H; Durmaz B; Bandehpour M; Özkınay F
Gene Ther; 2016 Jan; 23(1):10-7. PubMed ID: 26331341
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for spinal muscular atrophy: SMN and beyond.
Bowerman M; Becker CG; Yáñez-Muñoz RJ; Ning K; Wood MJA; Gillingwater TH; Talbot K;
Dis Model Mech; 2017 Aug; 10(8):943-954. PubMed ID: 28768735
[TBL] [Abstract][Full Text] [Related]
15. The loss of the snoRNP chaperone Nopp140 from Cajal bodies of patient fibroblasts correlates with the severity of spinal muscular atrophy.
Renvoisé B; Colasse S; Burlet P; Viollet L; Meier UT; Lefebvre S
Hum Mol Genet; 2009 Apr; 18(7):1181-9. PubMed ID: 19129172
[TBL] [Abstract][Full Text] [Related]
16. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.
Riessland M; Brichta L; Hahnen E; Wirth B
Hum Genet; 2006 Aug; 120(1):101-10. PubMed ID: 16724231
[TBL] [Abstract][Full Text] [Related]
17. Spinal muscular atrophy.
Vitte J; Attali R; Warwar N; Gurt I; Melki J
Adv Exp Med Biol; 2009; 652():237-46. PubMed ID: 20225030
[TBL] [Abstract][Full Text] [Related]
18. Salbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cells.
Harahap NIF; Nurputra DK; Ar Rochmah M; Shima A; Morisada N; Takarada T; Takeuchi A; Tohyama Y; Yanagisawa S; Nishio H
Biochem Biophys Rep; 2015 Dec; 4():351-356. PubMed ID: 29124224
[TBL] [Abstract][Full Text] [Related]
19. Therapeutics development for spinal muscular atrophy.
Sumner CJ
NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
[TBL] [Abstract][Full Text] [Related]
20. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
